Successful utilization of aliskiren, a direct renin inhibitor in Bartter syndrome.

Abstract

Bartter syndrome is traditionally treated with large doses of oral potassium with or without suppression of the renin-angiotensin system. Since plasma renin activity is invariably elevated in Bartter syndrome, the availability of the direct renin inhibitor aliskiren should lead to the ability to maintain potassium levels without utilizing large doses of oral potassium. This case report is, to my knowledge, the first to show the efficacy of a renin receptor blocker in Bartter syndrome.

• Authors: David S H Bell
• Journal: Southern medical journal (South Med J) Vol. 102 Issue 4 Pg. 413-5 (Apr 2009) ISSN: 1541-8243 [Electronic] United States
• PMID: 19279535 (Publication Type: Case Reports, Journal Article)

Chemical References

• Amides
• Antihypertensive Agents
• Fumarates
• aliskiren

Topics

• Amides (therapeutic use)
• Antihypertensive Agents (therapeutic use)
• Bartter Syndrome (drug therapy)
• Female
• Fumarates (therapeutic use)
• Humans
• Middle Aged
• Renin-Angiotensin System (drug effects)